A new clinical trial at the University of Michigan Rogel Cancer Center offers hope and a new treatment for patients with glioblastoma. This aggressive brain tumor is largely resistant to current treatment, almost always recurs, and comes with a grim prognosis. Daniel Wahl, M.D., Ph.D., lead physician, discusses the trial, their discovery of the causal relationship between high purine levels and glioblastoma radiation resistance, and how to leverage the relationship to make clinical treatments more effective.
